Drug Profile
Research programme: cancer therapeutics - Biosergen
Alternative Names: BE-14106Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Biosergen
- Class Macrocyclic lactams
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Norway
- 02 Apr 2013 Early research in Cancer in Norway (unspecified route)